share_log

Canopy Growth | DEFA14A: Others

Canopy Growth | DEFA14A:其他

SEC announcement ·  02/09 10:44
Moomoo AI 已提取核心信息
Canopy Growth Corporation reported its financial results for the third quarter of fiscal year 2024, ending December 31, 2023. The company saw a 9% year-over-year increase in Canada adult-use cannabis business-to-business net revenue and an 11% increase in Canada medical cannabis net revenue. Despite a 7% decline in consolidated net revenue year-over-year, gross margins improved significantly, with consolidated gross margins reaching 36% and Canada cannabis gross margins increasing to 28%. The company also reported a record quarter for medical sales and a 54% sequential increase in net revenue for Storz & Bickel, driven by strong sales of the new VENTY portable vaporizer. Free cash flow from continuing operations improved by 57% year-over-year, and the company reduced overall debt by $69MM during the quarter...Show More
Canopy Growth Corporation reported its financial results for the third quarter of fiscal year 2024, ending December 31, 2023. The company saw a 9% year-over-year increase in Canada adult-use cannabis business-to-business net revenue and an 11% increase in Canada medical cannabis net revenue. Despite a 7% decline in consolidated net revenue year-over-year, gross margins improved significantly, with consolidated gross margins reaching 36% and Canada cannabis gross margins increasing to 28%. The company also reported a record quarter for medical sales and a 54% sequential increase in net revenue for Storz & Bickel, driven by strong sales of the new VENTY portable vaporizer. Free cash flow from continuing operations improved by 57% year-over-year, and the company reduced overall debt by $69MM during the quarter. Canopy Growth reaffirmed its expectation to achieve positive Adjusted EBITDA in each business unit by the end of FY2024. A special shareholder meeting is scheduled for April 12, 2024, to move forward with the Canopy USA strategy. The company also announced the appointment of two new board members, Willy Kruh and Luc Mongeau, effective February 7, 2024.
Canopy Growth Corporation公布了截至2023年12月31日的2024财年第三季度的财务业绩。该公司的加拿大成人用大麻企业对企业净收入同比增长9%,加拿大医用大麻净收入增长11%。尽管合并净收入同比下降了7%,但毛利率却显著提高,合并毛利率达到36%,加拿大大麻毛利率增至28%。该公司还报告称,在新款VENTY便携式蒸发器的强劲销售的推动下,医疗销售创下了创纪录的季度,Storz & Bickel的净收入连续增长了54%。来自持续经营业务的自由现金流同比增长了57%,该公司在本季度的总债务减少了6,900万美元。Canopy Growth重申了其预期,即在 FY2024 结束之前,每个业务部门的调整后息税折旧摊销前利润将实现正数。计划于2024年4月12日举行特别股东大会,以推进Canopy USA的战略。该公司还宣布任命两名新的董事会成员,威利·克鲁和卢克·蒙戈,自2024年2月7日起生效。
Canopy Growth Corporation公布了截至2023年12月31日的2024财年第三季度的财务业绩。该公司的加拿大成人用大麻企业对企业净收入同比增长9%,加拿大医用大麻净收入增长11%。尽管合并净收入同比下降了7%,但毛利率却显著提高,合并毛利率达到36%,加拿大大麻毛利率增至28%。该公司还报告称,在新款VENTY便携式蒸发器的强劲销售的推动下,医疗销售创下了创纪录的季度,Storz & Bickel的净收入连续增长了54%。来自持续经营业务的自由现金流同比增长了57%,该公司在本季度的总债务减少了6,900万美元。Canopy Growth重申了其预期,即在 FY2024 结束之前,每个业务部门的调整后息税折旧摊销前利润将实现正数。计划于2024年4月12日举行特别股东大会,以推进Canopy USA的战略。该公司还宣布任命两名新的董事会成员,威利·克鲁和卢克·蒙戈,自2024年2月7日起生效。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息